Obermatt
See Similar Stocks →

Seer

NSQ:SEER · US81578P1066
Life Sciences Tools & ServicesSmall

360

43
EV / EBIT100
Price / Owner Earnings39
Owner Earnings Yield1
Dividend Yield1
Price/Sales39
Price/Book85
Return on Capital12
Cash Return on Capital20
Return on Equity32
Profit margins6
Accruals93
Owner Earnings Margin1
Sales growth25
Profit growth28
Reinvestment34
Price momentum23
Debt load77
Refinancing80
Debt Payback1
Liquidity51
Analyst ratings100
Opinion Changes100
Price Target Upside90
Market mood21
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Seer doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2017
Employees122
Websiteseer.bio
ISINUS81578P1066
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Machine LearningArtificial IntelligenceBiomedical EngineeringDetectors, Sensors and MemsPredictive AnalyticsHealth DiagnosticsProcess AutomationGeneticsMobileSaaSSmall and Medium Businesses

Description

Seer, Inc. operates as a life sciences organization focused on capturing deep molecular insights from the proteome to enable novel discoveries and breakthroughs in the understanding of biology and disease. The company, through its product, the Prote…

Analysis

Middle-of-the-road

Seer, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 2/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
68
2023202420252026

All-time high

76

Jan 2025

All-time low

16

Jan 2024

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
39
18
31
1
Price/Earnings
48
91
91
26
Price/Book
85
94
91
83
Dividend Yield
1
1
1
1
Value (overall)
50
53
61
41

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Seer with its peers
10x Genomics
NSQ:TXG
38
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Avantor
NYQ:AVTR
13
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Edgewise Therapeutics
NSQ:EWTX
49
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Nautilus Biotechnology
NAQ:NAUT
26
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Agilent
NYQ:A
89
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Bionano Genomics
NAQ:BNGO
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →